GLAXO

Glaxosmithkline Pharmaceuticals Ltd.

NSE: GLAXO

BSE: 500660

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

2,928.20-29.6 (-1.00%)

8 Sep, 12:00 AM

Overview

Analysis Statements Technicals Forecast Peers Resources News

Stock Scores

Quality Score

86.3 / 100

Value Score

18.8 / 100

Price Momentum Score

71.5 / 100

QVM Score

66.2 / 100

Key Metrics

Market Cap

49605.50

P/E (TTM)

47.88

P/B

21.88

P/S (TTM)

12.59

EV/EBITDA

35.68

CAPE (5Y)

70.03

ROE (TTM)

49.11

ROCE (TTM)

58.54

ROA (TTM)

24.57

Avg 3Y ROE

49.54

Earnings 3Y CAGR

3.75

Sales 3Y CAGR

6.44

Sales 5Y CAGR

3.36

Debt/Equity

0.01

Consensus TP

2977.00

Strong Buy %

25.00

Promoter Holding

75.00

Pledged %

0.00

Stock Analysis

Fundamental analysis overview of Glaxosmithkline Pharmaceuticals Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views

Red Flags

Positive

Strong price momentum

Price Momentum score of 71.5 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term

What is Price Momentum score?

71.5 / 100

Analysts have been raising forward EPS estimates

Analyst EPS estimate (consensus) for forward EPS has increased by 1.41% in the last 3 months, indicating earnings momentum

What is Earnings upgrade (3M)?

High and stable ROE

The company reported strong ROE of 49.11% for 12-month ended 30 Jun 2026 and ROE declined marginally by -63 bps from 1 year ago

What is ROE (FY)?

High and improving operating margin

The company reported strong operating margin of 32.64% for 12-month ended 30 Jun 2026 and operating margin improved by 236 bps from 1 year ago

What is Operating profit margin?

Moderate EPS growth and above median growth of industry

The company delivered moderate EPS growth of 11.69% for 12-month ended 30 Jun 2026 and the growth was 4.49 percentage points higher than median growth of industry

What is EPS growth (1Y)?

Low Debt to Equity, not much change from last year

The company has low Debt to Equity of 0.01 as on 30 Jun 2026 and Debt to Equity remained same in the last 1 year

What is Debt to Equity?

Consistently pays dividend

The company has not missed dividend payments once in the last 10 financial years

What is Dividend streak?

Company is net cash

The company is net cash i.e., cash and cash equivalents exceed total debt indicating a healthy balance sheet

What is Net Debt ?

Negative

Expensive and at a premium to industry median P/E

PE TTM of 47.88 indicates that the stock is expensive on a standalone basis and is at a 50.66% premium to industry median P/E

What is P/E Ratio?

Median: 31.78

Value 47.88

-0.96721.13

Low revenue growth and lower than median growth of industry

The company delivered moderate revenue growth of 5.38% for 12-month ended 30 Jun 2026 and the growth was 5.21 percentage points lower than median growth of industry

What is Sales growth (1Y)?

Median: 10.59

Value 5.38

-99.6111701.8

Neutral

Company's earnings are of moderate quality

Earnings quality score of 55.5 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion

What is Earnings quality score?

55.5 / 100

Moderate dividend yield

The company has a moderate dividend yield of 1.95%

What is Dividend yield?

Financial Snapshot

See detailed analysis

Multi-year trends for Glaxosmithkline Pharmaceuticals Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY

Profit After Tax FY

ROE FY

EBITDA FY

Glaxosmithkline Pharmaceuticals Ltd. Shareholding Pattern

Quarterly breakdown of Glaxosmithkline Pharmaceuticals Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Promoter	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00
Indian Promoter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Foreign Promoter	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00
Institutions	11.67	12.34	12.24	12.31	12.44	12.54	12.55	12.77	12.91	12.81	12.71	12.57	12.58	12.66	12.52	11.58	11.38	11.52	11.69	11.80	12.31	12.59	12.55	12.34	12.30	12.59
Mutual Funds / UTI	4.61	4.81	4.53	3.99	3.87	4.07	4.06	4.18	4.17	4.06	3.82	4.12	3.96	4.25	4.81	4.50	4.51	4.71	4.98	4.96	5.17	5.17	5.05	4.77	4.73	4.87
FI/Bank/Insurance	6.76	6.78	1.21	1.31	1.44	1.44	1.44	1.43	1.44	0.02	6.64	6.12	6.31	5.99	5.17	4.04	3.27	2.68	2.29	2.25	2.60	2.41	2.53	2.67	2.72	2.79
Govt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.01	0.01	-	-	-	-	-	-	-	-	-	-
FII	0.30	0.23	0.98	1.54	1.59	1.61	1.72	2.04	2.18	2.16	2.17	2.28	2.28	2.41	2.50	2.93	3.48	4.02	4.36	4.50	4.52	4.89	4.80	4.63	4.62	4.79
Other Institutions	0.00	1.06	5.52	5.47	11.00	5.41	10.55	10.17	10.18	13.06	0.08	0.05	0.04	0.01	0.03	0.10	0.12	0.12	0.07	0.09	0.02	0.13	0.18	0.26	0.23	0.15
Non-Institution	13.33	12.66	12.76	12.69	12.56	12.46	12.45	12.23	12.09	12.19	12.29	12.43	12.43	12.34	12.49	13.43	13.62	13.48	13.30	13.19	12.69	12.41	12.45	12.66	12.70	12.41
Bodies Corporate	0.60	0.54	0.49	0.48	0.34	0.40	0.39	0.40	0.53	0.60	0.63	0.63	0.64	0.52	0.56	0.89	0.97	0.92	0.87	0.81	0.66	0.66	0.68	0.86	0.87	0.78
Others (incl. Retail) No. of shareholders	12.73 1,07,408	12.12 1,11,389	12.27 1,15,693	12.21 1,16,276	12.22 1,19,029	12.06 1,19,574	12.06 1,20,560	11.83 1,22,581	11.56 1,09,307	11.59 1,12,130	11.66 1,15,824	11.80 1,19,281	11.79 1,19,369	11.82 1,18,199	11.93 1,14,406	12.54 1,13,601	12.65 1,17,819	12.56 1,17,267	12.43 1,17,986	12.38 1,18,411	12.03 1,20,666	11.75 1,22,347	11.77 1,21,565	11.80 1,21,143	11.83 1,20,442	11.63 1,24,806

Holdings and Presence

Indices and prominent investors with a stake in this stock.

Index Presence

#	Index	Weight	Rank
1	SHI: Biotech	13.91%	2 / 15
2	Nifty Midcap 150	0.26%	127 / 149
3	NIFTY Large Midcap 250	0.13%	214 / 250
4	Nifty Total Market	0.05%	291 / 749
5	Nifty 500	0.05%	284 / 499

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Glaxosmithkline Pharmaceuticals Ltd. shares as reported to NSE and BSE.

Name	Date	Type	Price	Qty.	Value
Ishares Core Emerging Markets Mauritius Co	17 Oct 2022	sell	₹ 1,378.65	80.61 k	₹ 11.11 cr
Ishares Core Msci Emerging Markets Etf	17 Oct 2022	buy	₹ 1,378.65	80.61 k	₹ 11.11 cr
Ishares India Sc Mauritius Company	17 Oct 2022	sell	₹ 1,378.65	11.84 k	₹ 1.63 cr
Ishares Msci India Small-Cap Etf	17 Oct 2022	buy	₹ 1,378.65	11.84 k	₹ 1.63 cr
Ishares Core Emerging Markets Mauritius Co	11 Oct 2022	sell	₹ 1,393.45	77.73 k	₹ 10.83 cr
Ishares Core Msci Emerging Markets Etf	11 Oct 2022	buy	₹ 1,393.45	77.73 k	₹ 10.83 cr
Ishares India Sc Mauritius Company	11 Oct 2022	sell	₹ 1,393.45	11.42 k	₹ 1.59 cr
Ishares Msci India Small-Cap Etf	11 Oct 2022	buy	₹ 1,393.45	11.42 k	₹ 1.59 cr
Ishares Core Emerging Markets Mauritius Co	19 Sep 2022	sell	₹ 1,431.75	72.15 k	₹ 10.33 cr
Ishares Core Msci Emerging Markets Etf	19 Sep 2022	buy	₹ 1,431.75	72.15 k	₹ 10.33 cr

Corporate Actions

History of Glaxosmithkline Pharmaceuticals Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.

Dividend₹ 57/share
Record date: 29th May 2026Ex-date: 29th May 2026
Announced on: 13th May 2026
Dividend₹ 42/share
Record date: 30th May 2025Ex-date: 30th May 2025
Announced on: 13th May 2025
Dividend₹ 12/share
Record date: 7th Nov 2024Ex-date: 7th Nov 2024
Announced on: 24th Oct 2024
Dividend₹ 32/share
Record date: 31st May 2024Ex-date: 31st May 2024
Announced on: 17th May 2024
Dividend₹ 32/share
Record date: 30th Jun 2023Ex-date: 30th Jun 2023
Announced on: 17th May 2023

Company Profile

Overview of Glaxosmithkline Pharmaceuticals Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company has three product areas: vaccines, specialty and general medicine. Its general medicines business has...

Key personnel

Mr. Carson Dalton

Executive Vice President - Communications and Government Affairs

Mr. Rishikesh Jaiwant

Executive Vice President - Supply Chain Operations

Dr. Shalini Menon

Executive Vice President - Medical Affairs

Mr. Amit Pandey

Executive Vice President - Legal

Mr. Vibhuti Gupta

Vice President - Commercial Operations and Strategy

Ms. Sharmishta Mitra

Vice President - Paediatric Vaccines

Mr. Omkar Parnandiwar

Vice President - Adult Vaccines

Ms. Aparajita Rajput

Vice President - Technology

View all

Incorporated on

13 Nov 1924

Last Annual

31 Mar 2026

Last Interim

30 Jun 2026

No. of Employees

3,103

IPO date

03 Nov 1994

Free Float

4,12,91,265

Website

https://india-pharma.gsk.com/en-in/

Phone no.

+912224959595

Address

Dr Annie Besant Road, Worli, MUMBAI, 400030, India

Frequently Asked Questions

What is the current share price of Glaxosmithkline Pharmaceuticals Ltd.?

The current share price of Glaxosmithkline Pharmaceuticals Ltd. is ₹ 2,928.20 as of 8 Sep 2026.

What is the market capitalisation of Glaxosmithkline Pharmaceuticals Ltd.?

The market capitalisation of Glaxosmithkline Pharmaceuticals Ltd. stands at ₹ 49,605.50 Cr.

What is the PE ratio of Glaxosmithkline Pharmaceuticals Ltd.?

The Price-to-Earnings (PE) ratio of Glaxosmithkline Pharmaceuticals Ltd. is 47.88 as of the latest trailing twelve months data.

What is the ROE and ROCE of Glaxosmithkline Pharmaceuticals Ltd.?

Glaxosmithkline Pharmaceuticals Ltd. has a Return on Equity (ROE) of 49.11% and a Return on Capital Employed (ROCE) of 58.54% as per the latest financial reports.

What is the 52-week high and low of Glaxosmithkline Pharmaceuticals Ltd.?

The 52-week high of Glaxosmithkline Pharmaceuticals Ltd. is - and the 52-week low is -.

What is the dividend yield of Glaxosmithkline Pharmaceuticals Ltd.?

The dividend yield of Glaxosmithkline Pharmaceuticals Ltd. is 1.95% based on the current market price.

What is the FII and DII holding in Glaxosmithkline Pharmaceuticals Ltd.?

Foreign Institutional Investors (FII) hold 4.79%, Domestic Institutional Investors (DII) hold 7.66% and retail/public investors hold 11.63% of Glaxosmithkline Pharmaceuticals Ltd. shares.

What sector does Glaxosmithkline Pharmaceuticals Ltd. belong to?

Glaxosmithkline Pharmaceuticals Ltd. operates in the Healthcare sector. 75% of analysts have a Buy or Strong Buy rating on Glaxosmithkline Pharmaceuticals Ltd. with a consensus target price of ₹ 2,977.00, implying 1.67% upside from current levels.

What is the beta of Glaxosmithkline Pharmaceuticals Ltd.?

The beta of Glaxosmithkline Pharmaceuticals Ltd. is 0.41, indicating its price volatility relative to the broader market. Over the past 1 year, Glaxosmithkline Pharmaceuticals Ltd. has delivered an absolute return of 6.45%.

What is the RSI of Glaxosmithkline Pharmaceuticals Ltd.?

The 14-day Relative Strength Index (RSI) of Glaxosmithkline Pharmaceuticals Ltd. is 57.31, placing it in the neutral zone. An RSI above 70 is considered overbought and below 30 is considered oversold.